The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
A randomised, double blind, placebo controlled trial with vitamin D 3 as an add on treatment to interferon β-1b in patients with multiple sclerosis
Abstract
OBJECTIVES: To study the safety and efficacy of vitamin D3 as an add on therapy to interferon β-1b (IFNB) in patients with multiple sclerosis (MS). METHODS: 1 year, double blind, placebo controlled, randomised study in 66 MS patients. The primary outcomes were T2 burden of disease (BOD) on MRI scans, proportion of patients with serum levels of 25-hydroxyvitamin D (25(OH)D) ≥85 nmol/l or intact parathyroid hormone (PTH) ≤20 ng/l, and number of adverse events. Secondary outcomes were number of MRI enhancing T1 lesions and new T2 lesions, annual relapse rate, changes in the Expanded Disability Status Scale score, timed 25 foot walk test and timed 10 foot tandem walk tests. RESULTS: Median change in BOD was 287 mm(3) in the placebo group and 83 mm(3) in the vitamin D group (p=0.105). Serum levels of 25(OH)D increased from a mean of 54 (range 19-82) nmol/l to 110 (range 67-163) nmol/l in the vitamin D group. 84% of patients reached a serum 25(OH)D level >85 nmol/l in the vitamin D group and 3% in the placebo group (p<0.0001). Patients in the vitamin D group showed fewer new T2 lesions (p=0.286) and a significantly lower number of T1 enhancing lesions (p=0.004), as well as a tendency to reduced disability accumulation (p=0.071) and to improved timed tandem walk (p=0.076). There were no significant differences in adverse events or in the annual relapse rate. CONCLUSION: Vitamin D3 add on treatment to IFNB reduces MRI disease activity in MS. TRIAL REGISTRATION NUMBER: EudraCT number 2007-001958-99 and ClinicalTrialsGov number NCT01339676.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20703 · Cited by 5,017
Self-citationSerum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis
Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., & Ascherio, A. (2006) · JAMA · doi:10.1001/jama.296.23.2832 · Cited by 1,897
Diagnostic criteria for multiple sclerosis
Poser, C. M., & Brinar, V. V. (2001) · Clinical Neurology and Neurosurgery · doi:10.1016/s0303-8467(00)00125-6 · Cited by 1,283
Vitamin D intake and incidence of multiple sclerosis
Munger, K. L., Zhang, S. M., O’Reilly, E., Hernán, M. A., Olek, M. J., Willett, W. C., & Ascherio, A. (2004) · Neurology · doi:10.1212/01.wnl.0000101723.79681.38 · Cited by 1,093
Cantorna, M. T., Hayes, C. E., & DeLuca, H. F. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7861 · Cited by 718
Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis
Simpson, S., Blizzard, L., Otahal, P., Van der Mei, I., & Taylor, B. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2011.240432 · Cited by 718
Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study
van der Mei, I. A. F., Ponsonby, A.-L., Dwyer, T., Blizzard, L., Simmons, R., Taylor, B. V., Butzkueven, H., & Kilpatrick, T. (2003) · BMJ · doi:10.1136/bmj.327.7410.316 · Cited by 551
Higher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis
Simpson, S., Taylor, B., Blizzard, L., Ponsonby, A., Pittas, F., Tremlett, H., Dwyer, T., Gies, P., & van der Mei, I. (2010) · Annals of Neurology · doi:10.1002/ana.22043 · Cited by 457
A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis
Burton, J. M., Kimball, S., Vieth, R., Bar-Or, A., Dosch, H.-M., Cheung, R., Gagne, D., D'Souza, C., Ursell, M., & O'Connor, P. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e1cec2 · Cited by 360
Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis
Smolders, J., Menheere, P., Kessels, A., Damoiseaux, J., & Hupperts, R. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458508094399 · Cited by 340
Cited by
ESPEN guideline clinical nutrition in neurology
Burgos, R., Bretón, I., Cereda, E., Desport, J. C., Dziewas, R., Genton, L., Gomes, F., Jésus, P., Leischker, A., Muscaritoli, M., et al. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2017.09.003 · Cited by 571
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression
Ascherio, A., Munger, K. L., White, R., Köchert, K., Simon, K. C., Polman, C. H., Freedman, M. S., Hartung, H.-P., Miller, D. H., Montalbán, X., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5993 · Cited by 516
Vitamin D and Multiple Sclerosis: A Comprehensive Review
Sintzel, M. B., Rametta, M., & Reder, A. T. (2018) · Neurology and Therapy · doi:10.1007/s40120-017-0086-4 · Cited by 435
Multiple sclerosis: Pathology, diagnosis and treatments
Huang, W.-J., Chen, W.-W., & Zhang, X. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4410 · Cited by 351
An Update on Vitamin D Metabolism
Saponaro, F., Saba, A., & Zucchi, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186573 · Cited by 308
Metadata
- Authors
- Soilu-Hänninen, M., Åivo, J., Lindström, B.-M., Elovaara, I., Sumelahti, M.-L., Färkkilä, M., Tienari, P., Atula, S., Sarasoja, T., Herrala, L., Keskinarkaus, I., Kruger, J., Kallio, T., Rocca, M. A., & Filippi, M.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2012-02-22
- Volume
- 83
- Issue
- 5
- Pages
- 565-571
- ISSN
- 0022-3050 (ISSN-L)
- 1468-330X
- OpenAlex
- W2097284781
- Cited by
- 269
- References
- 31
- FWCI
- 23.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomised, double blind, placebo controlled trial with vitamin D 3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. https://app.cochat.ai/papers/10.1136/jnnp-2011-301876
- The paper
- Soilu-Hänninen, M., Åivo, J., Lindström, B.-M., Elovaara, I., Sumelahti, M.-L., Färkkilä, M., Tienari, P., Atula, S., Sarasoja, T., Herrala, L., Keskinarkaus, I., Kruger, J., Kallio, T., Rocca, M. A., & Filippi, M. (2012). A randomised, double blind, placebo controlled trial with vitamin D 3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2011-301876
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.